Imperial College London
Portrait Picture

Professor Shoumitro (Shoumi) Deb

Faculty of Medicine, Department of Brain Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 4161s.deb CV

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@misc{Deb:2022,
author = {Deb, S and Limbu, B and Roy, M and Lee, R and Roy, A and Taiwo, O},
title = {Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: A systematic review and meta-analysis.},
type = {Poster},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - GEN
AB  - Background Around 9% of people with autism spectrum disorder (ASD) receive mood stabilisers/antiepileptic medications such as sodium valproate despite lack of evidence to suggest psychotropic medications including mood stabilisers are effective in individuals with ASD.Aims A systematic review and meta-analysis were carried out on the RCTs that assessed the effectiveness of mood stabilisers including lithium in people with ASD.Method The following databases were searched: Cochrane Library, MEDLINE, EMBASE, CINAHL, PsycINFO, ERIC, DARE, and ClinicalTrials.gov. Additionally, we hand-searched 12 relevant journals in the fields of intellectual disabilities, ASD and psychopharmacology. The Cochrane Risk of Bias tool and Jadad score were used to assess the quality of included RCTs. A meta-analysis was also carried out using a random-effects model.Results Eight RCTs were included in this systematic review (three on divalproex sodium, two on levetiracetam, and one each on sodium valproate, lamotrigine and topiramate) that included a total of 310 people with ASD, primarily children. No RCT on lithium was found. Outcomes were based on ASD core symptoms such as restrictive and repetitive behaviour, language and communication impairment, and associated symptoms such as irritability and agitation but not bipolar disorder or any other psychiatric disorders. Only two small studies (25%) from the same group showed definite superiority over placebo and one over psychoeducation alone. Meta-analysis of pooled data on Aberrant Behavior Checklist-Irritability subdomain score (ABC-I), Clinical Global Impression-Improvement (CGI-I), and Overt Aggression Scale (OAS)/OAS-Modified (OAS-M) did not show any significant intergroup difference. The rates of adverse effects did not show any significant intergroup difference.Conclusions It is difficult to draw any definitive conclusion about the effectiveness of mood stabilisers including lithium and antiepileptic medications to treat either ASD cor
AU  - Deb,S
AU  - Limbu,B
AU  - Roy,M
AU  - Lee,R
AU  - Roy,A
AU  - Taiwo,O
PY  - 2022///
TI  - Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: A systematic review and meta-analysis.
ER  -
Download